RxDoctor Payments Data

Abdul Rashid, MD

Cardiovascular Disease · Desoto, TXNPI 1821288085

Payments from drug & device makers

$3,191in general payments, 2019–2025

Across 87 payments — averaging $36.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$401
  • Merck$400
  • Abiomed$208
  • Medtronic$151
  • Pfizer$140
  • plus $860 from 17 others

What the payments were for

  • Travel & lodging$81225%
  • Food & beverage$2,29172%
  • Education$873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,191 in reported general payments places this provider in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$79,769
Medicare patients
339
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$85,572
EntrestoSacubitril/Valsartan24$37,540
Metoprolol Succinate128$1,669
Isosorbide Mononitrate ErIsosorbide Mononitrate69$645
Rosuvastatin Calcium17$592
Hydralazine Hcl18$451
Atorvastatin Calcium56$370
Losartan Potassium41$366
Amlodipine Besylate66$342
ClopidogrelClopidogrel Bisulfate45$335
Isosorbide Dinitrate11$316
Carvedilol56$313
Furosemide83$290
Cilostazol17$271
Clonidine Hcl18$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$85,57279 claims
NovartisEntresto$85$37,54024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Desoto

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →